AU2022300325A1 - Process for the preparation of nlrp3 inhibitors - Google Patents
Process for the preparation of nlrp3 inhibitors Download PDFInfo
- Publication number
- AU2022300325A1 AU2022300325A1 AU2022300325A AU2022300325A AU2022300325A1 AU 2022300325 A1 AU2022300325 A1 AU 2022300325A1 AU 2022300325 A AU2022300325 A AU 2022300325A AU 2022300325 A AU2022300325 A AU 2022300325A AU 2022300325 A1 AU2022300325 A1 AU 2022300325A1
- Authority
- AU
- Australia
- Prior art keywords
- group
- piperidine
- typically
- solvent
- protected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/98—Nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202141028180 | 2021-06-23 | ||
| IN202141028180 | 2021-06-23 | ||
| PCT/EP2022/067126 WO2022268935A2 (en) | 2021-06-23 | 2022-06-23 | Novel process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2022300325A1 true AU2022300325A1 (en) | 2023-11-02 |
| AU2022300325A8 AU2022300325A8 (en) | 2023-11-16 |
Family
ID=82458485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022300325A Pending AU2022300325A1 (en) | 2021-06-23 | 2022-06-23 | Process for the preparation of nlrp3 inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240150291A1 (https=) |
| EP (1) | EP4359385A2 (https=) |
| JP (1) | JP2024524215A (https=) |
| KR (1) | KR20240024842A (https=) |
| CN (1) | CN118019727A (https=) |
| AR (1) | AR126215A1 (https=) |
| AU (1) | AU2022300325A1 (https=) |
| CA (1) | CA3219597A1 (https=) |
| IL (1) | IL308071A (https=) |
| MX (1) | MX2023014547A (https=) |
| TW (1) | TW202317514A (https=) |
| WO (1) | WO2022268935A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR128498A1 (es) * | 2022-02-15 | 2024-05-15 | Hoffmann La Roche | Procesos novedosos |
| WO2024133610A1 (en) * | 2022-12-23 | 2024-06-27 | F. Hoffmann-La Roche Ag | Proccesses for the preparation of an nlrp3 inhibitor |
| IL325043A (en) | 2023-08-16 | 2026-01-01 | Hoffmann La Roche | Process for the preparation of 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indecen-4-yl)carbamoyl)piperidine-4-sulfonamide |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69727837T2 (de) * | 1997-05-02 | 2004-12-30 | Dr. Reddy's Research Foundation, Hyderabad | Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel |
| HUP0303204A3 (en) * | 2000-11-16 | 2010-04-28 | Sankyo Co | 1-methylcarbapenem derivatives and pharmaceutical compositions containing them |
| WO2002100833A1 (en) * | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Rho KINASE INHIBITORS |
| US7220735B2 (en) * | 2002-04-18 | 2007-05-22 | Schering Corporation | Benzimidazolone histamine H3 antagonists |
| TW200524865A (en) * | 2003-10-08 | 2005-08-01 | Nicholas Piramal India Ltd | Fibrinogen receptor antagonists and their use |
| DOP2006000009A (es) * | 2005-01-13 | 2006-08-15 | Arena Pharm Inc | Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina |
| JP5508027B2 (ja) * | 2007-02-22 | 2014-05-28 | メルク セローノ ソシエテ アノニム | キノキサリン化合物及びその使用 |
| JP5898962B2 (ja) * | 2012-01-11 | 2016-04-06 | 東京応化工業株式会社 | レジスト組成物及びレジストパターン形成方法 |
| WO2017095758A1 (en) * | 2015-12-01 | 2017-06-08 | Merck Sharp & Dohme Corp. | Homobispiperidinyl derivatives as liver x receptor beta agonists, compositions, and their use |
| US11465992B2 (en) * | 2017-07-07 | 2022-10-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| GB201712282D0 (en) * | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
| EP3668861A1 (en) * | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| EP3773576A4 (en) * | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| CR20200588A (es) * | 2018-05-04 | 2021-06-24 | Inflazome Ltd | Compuestos novedosos |
| CA3113573A1 (en) * | 2018-09-21 | 2020-03-26 | Novartis Ag | Isoxazole carboxamide compounds and uses thereof |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| GB201819083D0 (en) * | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| WO2020157069A1 (en) * | 2019-01-28 | 2020-08-06 | NodThera Limited | Amino heterocyclic compounds and uses thereof |
-
2022
- 2022-06-23 WO PCT/EP2022/067126 patent/WO2022268935A2/en not_active Ceased
- 2022-06-23 EP EP22738569.7A patent/EP4359385A2/en active Pending
- 2022-06-23 IL IL308071A patent/IL308071A/en unknown
- 2022-06-23 TW TW111123528A patent/TW202317514A/zh unknown
- 2022-06-23 CA CA3219597A patent/CA3219597A1/en active Pending
- 2022-06-23 KR KR1020237044161A patent/KR20240024842A/ko active Pending
- 2022-06-23 JP JP2023578919A patent/JP2024524215A/ja active Pending
- 2022-06-23 CN CN202280045202.0A patent/CN118019727A/zh active Pending
- 2022-06-23 AU AU2022300325A patent/AU2022300325A1/en active Pending
- 2022-06-23 AR ARP220101651A patent/AR126215A1/es unknown
- 2022-06-23 MX MX2023014547A patent/MX2023014547A/es unknown
-
2023
- 2023-12-19 US US18/545,711 patent/US20240150291A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022268935A3 (en) | 2023-02-02 |
| IL308071A (en) | 2023-12-01 |
| TW202317514A (zh) | 2023-05-01 |
| EP4359385A2 (en) | 2024-05-01 |
| US20240150291A1 (en) | 2024-05-09 |
| CN118019727A (zh) | 2024-05-10 |
| AR126215A1 (es) | 2023-09-27 |
| KR20240024842A (ko) | 2024-02-26 |
| AU2022300325A8 (en) | 2023-11-16 |
| WO2022268935A2 (en) | 2022-12-29 |
| CA3219597A1 (en) | 2022-12-29 |
| JP2024524215A (ja) | 2024-07-05 |
| MX2023014547A (es) | 2024-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022300325A1 (en) | Process for the preparation of nlrp3 inhibitors | |
| DK2593429T3 (en) | A process for preparing a biphenyl-2-ylcarbamic acid | |
| KR20200057705A (ko) | 리보시클립 및 그의 염의 제조를 위한 개선된 방법 | |
| EA034169B1 (ru) | Синтез полициклических карбамоилпиридоновых соединений | |
| CN110139868B (zh) | 制备3-取代的5-氨基-6H-噻唑并[4,5-d]嘧啶-2,7-二酮化合物的方法 | |
| WO2022214645A1 (en) | Processes and intermediates for the preparation of relugolix | |
| CN102203062A (zh) | 用于合成8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮化合物的方法和中间体 | |
| CN106220624A (zh) | 阿哌沙班合成中的关键中间体和杂质：阿哌沙班二醇酯 | |
| US20240400516A1 (en) | Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivataives | |
| EP4638422A1 (en) | Proccesses for the preparation of an nlrp3 inhibitor | |
| HK40105889A (zh) | 用於制备nlrp3抑制剂的方法 | |
| JP2016172755A (ja) | 抗ウイルス化合物およびその有用な中間体の調製方法 | |
| CN121202865A (zh) | 非唑奈坦及其中间体的制备方法和中间体 | |
| CN118234729A (zh) | 用于制备双环甘氨酸-脯氨酸化合物和其单环甘氨酸-脯氨酸中间体的方法 | |
| WO2025240465A1 (en) | Processes for preparing macrocyclic compounds | |
| HK40012866B (en) | Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds | |
| HK40012866A (en) | Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds | |
| CN102464691A (zh) | 制备抗病毒组合物的方法及其中间体的应用 | |
| HK1217493A1 (zh) | 製備抗病毒組合物的方法及其中間體的應用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 57 , NO 43 , PAGE(S) 6203 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME HOFFMANN-LA ROCHE INC., APPLICATION NO. 2022300325, UNDER INID (71) ADD CO-APPLICANT F. HOFFMANN-LA ROCHE AG |